ArticleBMC ophthalmology2026
Combined phacogoniosynechialysis with viscocanalostomy and Ologen implant for the management of primary angle-closure glaucoma: a retrospective cohort pilot study.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedical treatment is ineffective in controlling the intraocular pressure (IOP) in primary angle-closure glaucoma (PACG) with extensive peripheral anterior synechia (PAS), and surgery should be considered. This study aimed to evaluate the efficacy and safety of phacogoniosynechialysis (Phaco-GSL) with viscocanalostomy and Ologen implant for the management of medically uncontrolled PACG with PAS ≥ 270°.
methodsThis retrospective cohort study included 27 eyes from 27 patients with PACG who had one eye with medically uncontrolled PACG with or without cataract. These eyes had ≥ 270° of PAS, the IOP was above 21 mmHg with maximum topical antiglaucoma treatment or less than 21 mmHg with glaucoma medication intolerance. All eyes were treated with Phaco-GSL combined with viscocanalostomy and an Ologen implant. The follow-up period was one year.
resultsOne year postoperatively, complete success was achieved in 19 cases (70.4%), qualified success in 6 cases (22.2%), and failure in 2 cases (7.4%). The mean decrease in IOP was 13.33 ± 4.07 mmHg, the mean reduction of antiglaucoma medications was 2.74 ± 1.10, and the mean percentage of reduction in IOP was 48.11 ± 9.85%. There was a statistically significant decrease in IOP and antiglaucoma medications. Malignant glaucoma occurred in three patients. It was treated successfully; other complications were trivial. Goniopuncture was needed after surgery in 18 eyes (66.7%) to control the IOP.
conclusionPhaco-GSL with viscocanalostomy with Ologen implant is an effective procedure in PACG to reach the target IOP and decrease the number of antiglaucoma medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.